Get the Stockscreener App
360.45
0.81%
-2.94
After Hours:
360.45
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $360.45, with a volume of 1.69M.
It is down -0.81% in the last 24 hours and up +1.48% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$363.39
Open:
$363.04
24h Volume:
1.69M
Relative Volume:
0.64
Market Cap:
$194.54B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
25.07
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-1.63%
1M Performance:
+1.48%
6M Performance:
+11.15%
1Y Performance:
+22.07%
1-Day Range:
$355.73
$363.29
1-Week Range:
$355.73
$375.25
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
360.45 | 196.12B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,181.87 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.77 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.00 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
124.03 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.37 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Recalls Corlanor And Sensipar Nationwide Over Quality Control Issues - simplywall.st
Amgen Faces a July 29 Deadline to Save Tavneos From an FDA Withdrawal. Here’s What It Means for the Stock. - TIKR.com
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
Guggenheim Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Guggenheim raises Amgen stock price target to $343 on product mix - Investing.com
AMGN DCF Analysis: Intrinsic Value $292 vs Price $363 - GuruFocus
BofA raises Amgen stock price target on growth franchise execution By Investing.com - Investing.com Nigeria
BofA raises Amgen stock price target on growth franchise execution - Investing.com
J. Safra Sarasin Holding AG Sells 38,033 Shares of Amgen Inc. $AMGN - MarketBeat
Absher Wealth Management LLC Trims Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance? - The Motley Fool
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term story - ad-hoc-news.de
Castleview Partners LLC Has $2.77 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Ferguson Wellman Capital Management Inc. - MarketBeat
Cullinan Associates Inc. Has $8.98 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Fifth Third Bancorp Acquires 167,835 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as investors await the next catalyst - ad-hoc-news.de
Amgen stock steadies as the biotech group leans on scale - ad-hoc-news.de
Amgen Inc. $AMGN Shares Sold by Torray Investment Partners LLC - MarketBeat
Candriam S.C.A. Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Conning Inc. Has $33.85 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as biotech pipeline and U.S. market listing shape long-term investor expect - ad-hoc-news.de
Amgen's Biotech Crossroads: Congressional Divergence Amid Patent Cliffs and Pipeline Promise - Kavout | AI
ETFs Investing in Amgen Inc. Stocks - TradingView
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term growth narr - ad-hoc-news.de
Amgen stock reflects biotech heavyweight's steady role in US healthcare - ad-hoc-news.de
Munich Reinsurance Co Stock Corp in Munich Sells 2,916 Shares of Amgen Inc. $AMGN - MarketBeat
Ibex Wealth Advisors Increases Stake in Amgen Inc. $AMGN - MarketBeat
First Horizon Corp Boosts Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Regeneron Cites Medtronic Ruling In Amgen Bundling Case - Law360
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
How AI Is Changing Drug Discovery and What It Will Take to Unlock Its Full Potential - Amgen
Truist Raises its Price Target on Amgen (AMGN) - Insider Monkey
Amgen (AMGN): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Amgen stock responds to obesity drug progress and solid pipeline momentum - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Greenwood Capital Associates LLC Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen highlights its biotech pipeline as a driver for long-term growth - Ad-hoc-news.de
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370 - Moomoo
Amgen highlights oncology pipeline progress as a major biotech on Nasdaq - Ad-hoc-news.de
The Future of Genus Patenting Strategies for Antibodies Post- Amgen - IPWatchdog.com
Amgen Ecovation®: How Amgen Builds Sustainability Into Biotech - Amgen
Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar - Bloomberg Law News
Amgen extends its biotech footprint as a major U.S. pharma player - Ad-hoc-news.de
Amgen Inc. $AMGN Holdings Cut by Swedbank AB - MarketBeat
Amgen Inc. focuses on biotechnology leadership as investors track long-term growth drivers - Ad-hoc-news.de
Amgen focuses on long-term growth as a leading biotech innovator - Ad-hoc-news.de
Amgen (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary - Quartr
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims - Law360
How Safe Is Amgen's Dividend? - The Motley Fool
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):